Omacetaxine Mepesuccinate
(OH-mah-seh-TAK-seen MEH-peh-SUK-sih-nayt)
This page contains brief information about omacetaxine mepesuccinate and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.
| US Brand Name(s): |  | Synribo |
| | ||
| | ||
| FDA Approved: | | Yes |
FDA Approval for Omacetaxine Mepesuccinate
Use in CancerOmacetaxine mepesuccinate is approved to treat:
- Chronic myelogenous leukemia. It is used in some patients who have been treated with at least two drugs called tyrosine kinase inhibitors and have not gotten better.
Omacetaxine mepesuccinate is also being studied in the treatment of other types of cancer.
More About Omacetaxine MepesuccinateDefinition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.
Clinical Trials Accepting PatientsFind Clinical Trials for Omacetaxine Mepesuccinate - Check for trials from NCI's list of cancer clinical trials now accepting patients.
Important: The drug information on this page is meant to be educational. It is not a substitute for medical advice. The information may not cover all possible uses, actions, interactions, or side effects of this drug, or precautions to be taken while using it. Please see your health care professional for more information about your specific medical condition and the use of this drug.
Back to Top
